Your session is about to expire
← Back to Search
Lurbinectedin for Small Cell Lung Cancer
Study Summary
This trial is testing a new combination treatment for small cell lung cancer that has progressed after first-line treatment. The goal is to find the maximum tolerated dose and to see if the combination is safe and effective.
- Small Cell Lung Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the historical context of Nivolumab research?
"There are 805 clinical trials currently studying Nivolumab. 88 of those are in the critical third phase. The majority of these medical studies originate from Pittsburgh, however there are 43586 locations worldwide where research is being conducted."
How many people can join this clinical trial at the most?
"Yes, as of 11/2/2022, this study is still actively recruiting patients that meet the eligibility criteria. The trial was first posted on 11/23/2020. Currently, 57 participants are needed from 2 different locations."
Can people with the required qualifications join this trial at this time?
"This particular clinical trial, which was first announced on November 23rd, 2020 is currently looking for study participants. The listing was most recently updated on November 2nd, 2022."
What are the primary cancers that Nivolumab is designed to target?
"Nivolumab can be used as a treatment for patients that have unresectable melanoma, malignant neoplasms, and have undergone anti-angiogenic therapy."
Share this study with friends
Copy Link
Messenger